February 9, 2006 Vanderbilt University, Brigham Young University and Ceragenix Pharmaceuticals have announced that one of a family of compounds, called Ceragenins (or CSAs) shows potent virucidal activity in in vitro laboratory tests against multiple strains of Human Immunodeficiency Virus (HIV), the virus that causes AIDS. CSAs were invented by Dr. Paul D. Savage of Brigham Young University's Department of Chemistry and Biochemistry and exclusively licensed to Ceragenix. In data previously presented by Dr. Savage and other researchers, CSAs have been shown to have broad spectrum antibacterial activity. Dr. Derya Unutmaz, Associate Professor of Microbiology and Immunology at the Vanderbilt University School of Medicine, tested several CSAs in his laboratory for their ability to kill HIV directly and whilst cautious, acknowledged that CSAs could be the breakthrough technology to combat HIV/AIDS researchers the world has been waiting for.
Read the full article: Potential HIV-AIDS cure - drug found to kill multiple HIV strains